A BST RACT : Background: Cognitive dysfunction is common in progressive supranuclear palsy, but the influence of genetics on cognition in this disorder has not been well studied. The objective of this study was to investigate the effect of genes previously identified as risk alleles, including microtubule-associated protein tau, myelin-associated oligodendrocyte basic protein, eukaryotic translation initiation factor 2-alpha kinase 3, and syntaxin 6, as well as apolipoprotein E, on cognitive function in progressive supranuclear palsy. Methods: The sample was composed of 305 participants who met criteria for possible or probable progressive supranuclear palsy. Genetic information was determined by TaqMan genotyping assays. A neuropsychological battery was administered to all study participants. Measures included in the battery evaluated for general cognition, executive function, memory, attention, language, and visuospatial ability. Results: Cognition did not vary significantly between individuals homozygous or heterozygous for the microtubule-associated protein tau H1 haplotype. However, cognition varied significantly at the subhaplotype level, with carriers of the microtubule-associated protein tau rs242557/A allele, which marks the H1c subhaplotype, performing better than noncarriers on measures of general cognitive function, executive function, and attention. No associations were found for other genes.
A BST RACT : Background: Cognitive dysfunction is common in progressive supranuclear palsy, but the influence of genetics on cognition in this disorder has not been well studied. The objective of this study was to investigate the effect of genes previously identified as risk alleles, including microtubule-associated protein tau, myelin-associated oligodendrocyte basic protein, eukaryotic translation initiation factor 2-alpha kinase 3, and syntaxin 6, as well as apolipoprotein E, on cognitive function in progressive supranuclear palsy. Methods: The sample was composed of 305 participants who met criteria for possible or probable progressive supranuclear palsy. Genetic information was determined by TaqMan genotyping assays. A neuropsychological battery was administered to all study participants. Measures included in the battery evaluated for general cognition, executive function, memory, attention, language, and visuospatial ability. Results: Cognition did not vary significantly between individuals homozygous or heterozygous for the microtubule-associated protein tau H1 haplotype. However, cognition varied significantly at the subhaplotype level, with carriers of the microtubule-associated protein tau rs242557/A allele, which marks the H1c subhaplotype, performing better than noncarriers on measures of general cognitive function, executive function, and attention. No associations were found for other genes.
Conclusions:
The results of the current study indicate that variations in microtubule-associated protein tau influence cognition in progressive supranuclear palsy. Although the H1c-specific rs242557/A allele is a risk factor for progressive supranuclear palsy, carriers of this allele may exhibit better cognition than non-carriers in patients with the atypical parkinsonian syndrome. Further studies are needed. V C 2017 International Parkinson and Movement Disorder Society K e y W ord s: progressive supranuclear palsy; MAPT; cognition; GWAS Progressive supranuclear palsy (PSP) is a rare neurodegenerative disorder that primarily affects adults older than 60 years. 1 Individuals with the PSPRichardson phenotype (PSP-RS) present with postural instability and falls, parkinsonism not responding to dopaminergic therapy, and slowing of vertical saccades. 2 PSP is considered a tauopathy because of the accumulation of tau protein within neurons and glia in certain brain regions (eg, basal ganglia, brain stem). 3 PSP is a primary tauopathy, with tau being the primary protein that aggregates in the brain. In contrast, secondary tauopathies are characterized by accumulation of tau in combination with other protein aggregates. For example, Alzheimer's disease is characterized by the accumulation in the brain of both tau and amyloid-beta (Ab).
Although PSP is most often characterized as a movement disorder, cognitive dysfunction is common. 1, [4] [5] [6] Consistent with prior studies, our group demonstrated that up to half of patients with PSP exhibit some level of general cognitive impairment in the early stages. 5 Executive dysfunction was particularly prominent, with milder difficulties noted in verbal memory, construction, and language. This previous study by our group supported an earlier large-scale study of cognition in PSP. 6 Results of a genome-wide association study (GWAS) of autopsy-proven cases of PSP identified several singlenucleotide polymorphisms as risk alleles: microtubuleassociated protein tau (MAPT) rs8070723 and rs242557, myelin-associated oligodendrocyte basic protein (MOBP) rs1768208, eukaryotic translation initiation factor 2-alpha kinase 3 (EIF2AK3) rs7571971, and syntaxin 6 (STX6) rs1411478 (3) . In this same study, certain alleles of APOE were less frequently present in PSP than in the general population. MAPT encodes tau, and the accumulation of tau in the brain has been linked to cognitive decline. [7] [8] [9] [10] The region of chromosome 17 encoding MAPT has 2 haplotypes, H1 and H2, which are in complete linkage disequilibrium because of an inversion variant. The H1 haplotype is strongly linked to PSP 11 and also affects the risk of mild cognitive impairment (MCI), 12 progression from MCI to dementia, 13 and progression from Parkinson's disease to Parkinson's disease dementia.
14 APOE is a strong genetic risk factor for AD and affects the rate at which Ab accumulates in the brain, which is inversely related to cognitive abilities. 15, 16 However, prior investigations into the associations of MAPT and APOE with cognition in PSP have been hindered by both sample size limitations and the evaluation of only general cognitive function. 17, 18 Although MOBP rs1768208 is associated with brain atrophy in patients with frontotemporal lobar degeneration, 19 its effect on cognition is not well understood, and its association with the cognitive dysfunction often seen in PSP has not been investigated. Finally, to our knowledge, the association of EIF2AK3 and STX6 with cognition has not been previously investigated in any patient group.
To address these knowledge gaps, we examined the association between cognition and MAPT, APOE, MOBP, EIF2AK3, and STX6 in a large sample of PSP patients. Commonly used neuropsychological tests measuring a wide range of abilities (eg, frontal/executive functioning, verbal memory, naming, general cognitive functioning) were utilized. Based on a review of the literature, we hypothesized that cognition would be poorer for those patients with MAPT H1/H1 and/ or APOE e4. Because of the lack of existing studies on the topic, analyses investigating the role of MOBP, EIF2AK3 and STX6 were considered exploratory. 22 score 24 was also required for inclusion. This MMSE cutoff score was intended to limit the number of PSP patients with dementia. Participants were also excluded if they had other central nervous system disorders or were unable to provide informed consent. Three hundred five of the 350 PSP patients had genetic data collected and were included in this study. Autopsies were conducted on 20 patients, with 18 showing PSP pathology. The other 2 patients showed corticobasal degeneration pathology, which is another 4R-tauopathy that can present clinically with a PSP phenotype.
Methods Participants
After informed consent, participants were evaluated by a clinical team consisting of a movement disorder specialist and trained research assistant who completed a detailed history and examination including the validated PSP Rating Scale (PSPRS) and Unified Parkinson's Disease Rating Scale (UPDRS). Finally, a baseline neuropsychological evaluation was completed by medical personnel who had received training on the battery from a neuropsychologist. Accuracy of the evaluations was periodically checked at each site by a neuropsychologist.
Genotyping
Genotypes were determined by TaqMan genotyping assays (Life Technologies). Predesigned assays are: for rs242557 in MAPT, C__1016016_1; for rs8070723 in MAPT, C__29297996_10; for APOE rs7412, C__904973_10 and rs429358, C__3084793_20; for MOBP rs1768208, C___75367_10; and for EIF2AK3 rs7571971, C___20893_10. STX6 was genotyped by a custom assay design, ID AHGJ5AO, with the forward
primer, GGTAGGCAAAAGGTGCTATGGA; reverse primer, GTCCCAGCACCCTGTCAA; reporter 1 sequence, CCCAGAGAAGAAGAC; and reporter 2 sequence, CCAGAGGAGAAGAC.
Measures
The PSPRS assesses the level of impairment in PSP. 23 Impairment is assessed across 6 categories: health history, mentation, bulbar function, eye and lid movement, limb movement, and trunk movement, with most items rated on a 0-4 Likert scale (from 0 5 no presence of symptom to 4 5 severe presence of symptom). The total score is the sum of all items and ranges from 0 to 100. Higher scores indicate greater impairment.
The UPDRS was originally developed for use in evaluating impairment in Parkinson's disease, 24 but it has also been shown to be a valid and reliable measure when evaluating PSP patients. The UPDRS comprises 42 items, rated on a 0-4 Likert scale (from 0 5 no presence of symptom to 4 5 severe presence of symptom). Three categories are rated: mentation, behavior, and mood; activities of daily living; and motor functioning. A total score is the sum of all items and ranges from 0 to 124. Higher scores are indicative of greater impairment.
The Dementia Rating Scale-2 (DRS-2 25 is a measure of general cognitive functioning that yields a total score (ranges from 0 to 144) and scores on six subscales (ie, attention, initiation/perseveration, construction, conceptualization, and memory). For total as well as subscale scores, higher values indicate better cognitive functioning.
The Frontal Assessment Battery (FAB 26 assesses frontal lobe/executive function across 6 items (ie, similarities, lexical fluency, motor series, conflicting instructions, Go-No-Go, and prehension behavior). Each item is scored on a 3-point scale with 18 possible points making up the FAB total score. Higher scores indicate better cognition.
The California Verbal Learning Test -Second Edition, Short Form (CVLT-II SF) is a measure of verbal learning and memory in which subjects learn 9 words over 4 learning trials. 27 After a 10-minute delay, free recall of the list is queried. Higher scores indicate better memory. Although the CVLT-II SF yields many scores, the variables used in this analysis include total recall (ie, number of words correctly recalled across 4 learning trials) and long-delay free recall (ie, number of words correctly recalled after a 10-minute delay).
The Boston Naming Test (BNT 28 is a 60-item measure of confrontational naming. Higher scores indicate better naming abilities.
Data Analyses
In total, 4 sets of analyses were conducted. First, a series of chi-square tests was conducted to determine if distributions of sex and race differed by genotype (ie, racial status by genotype). Another series of chisquare tests was conducted to determine if differences in MAPT, APOE, MOBP, EIF2AK3, and STX6 were associated with differences in sex or racial distribution (ie, genotype by racial status). Second, a series of independent t tests was conducted to investigate the relationship between MAPT, APOE, MOBP, EIF2AK3, and STX6 with age, education, and disease severity (ie, UPDRS and PSPRS total scores). A second series of independent t tests was conducted to determine if differences in MAPT, APOE, MOBP, EIF2AK3, and STX6 were associated with varying levels of cognitive performance. A series of independent t tests was also conducted to determine if the combined effect of the H1c-specific rs242557/A allele and APOE e4/4 was significantly greater than the effect of rs242557/A alone. Third, to characterize the neurocognitive profiles of the total sample and of the different genetic phenotypes, descriptive statistics including means and standard deviation were calculated for neuropsychological measures. Finally, a series of binary logistic regression analyses was conducted to examine the association between MAPT rs242557 and cognition. For these regression analyses, race was entered into block 1 for the purpose of statistical control.
Of note, only 2 participants were MAPT H1 noncarriers (ie, were H2/H2), consistent with the dramatically reduced risk of PSP in H1 noncarriers. Thus, these 2 participants were not included in analyses conducted to examine the MAPT H1 subhaplotype.
An a priori Bonferroni adjustment was not employed for a number of reasons. Bonferroni assumes that each hypothesis test is independent, 29 and this assumption is virtually never met when conducting cognitive research. Bonferroni also applies only to the general null hypothesis, implies that a given comparison will be interpreted differently according to how many other tests were performed, and -most importantly -often unnecessarily inflates type II error rates. [30] [31] [32] Perneger 32 noted that "simply describing what tests of significance have been performed, and why, is generally the best way of dealing with multiple comparisons." Thus, because of the number of comparisons, an a priori 0.01 level of significance was applied to strike a balance between type I and type II error rates.
Results

Cohort Characteristics
None of the genotypes that we studied varied by sex or race (Table 1) , although MAPT rs242557, which tags the H1c subhaplotype, approached significance by race with a larger percentage of whites being rs242557/ A allele carriers than nonwhites. Mean disease duration and age at onset were 4.4 6 2.4 and 64.5 6 7.2 years, respectively.
Neither demographic variables (ie, age, education, sex, race) nor disease severity (ie, UPDRS and PSPRS total scores) differed according to MAPT (Table 2) or APOE, MOBP, EIF2AK3, or STX6 genotype (Table 3 ). Neither disease duration nor age at onset differed according to genetic information.
Neurocognitive Performance
We focused first on the effects of the MAPT genotype on neurocognitive performance (Table 4) . No differences were found between PSP patients at the haplotype level. However, aspects of cognition varied significantly according to MAPT subhaplotype. Participants who were MAPT rs242557/A allele carriers exhibited significantly better general cognitive functioning (ie, DRS-2 Total score), attention (ie, DRS-2 Attention), and general/basic executive function (ie, DRS-2 Initiation/Perseveration) than did noncarriers. Differences in visuospatial/constructional ability (ie, DRS-2 Construction), abstraction/judgment (ie, DRS-2 Conceptualization), and immediate recall for verbal list learning (ie, CVLT-2 SF Immediate Recall) approached significance, with carriers again performing better than noncarriers. Effects of the MAPT H1c-specific rs242557/A allele on DRS-2 Total (P 5 0.005) and DRS-2 Attention (P 5 0.009) remained significant in follow-up logistic regression analyses, with race being entered into block 1 for the purpose of statistical control. DRS-2 Initiation/Perseveration was no longer significant at the 0.01 level in logistic regression analysis but approached significance (P 5 0.028). No significant differences were found on any cognitive variables between rs242557/A homozygotes and rs242557/A heterozygotes. We next examined the effects of APOE, MOBP, EIF2AK3, and STX6 on cognition (Table 5) . Delayed recall for verbal list learning (ie, CVLT-2 Long Delay Free Recall) approached significance for EIF2AK3 rs7571971, with participants with T/T performing poorer than participants with either T/C or C/C. No other significant effects of genotype on cognitive performance were observed in this sample of patients with PSP.
G E N E T I C I N F L U E N C E S O N C O G N I T I O N I N P S P
The combined cognitive effect of the H1c-specific rs242557/A allele and APOE e4 carrier (n 5 177) was not significantly greater than the cognitive effect of the H1c-specific rs242557/A allele alone (n 5 233): DRS-2 Total (t 231 
Discussion
In the current study, we investigated the relationship between MAPT, APOE, MOBP, EIF2AK3, and STX6 and cognition in a large sample of patients with PSP. In a previous GWAS of autopsy-proven cases of PSP, risk alleles on MAPT, MOBP, EIF2AK3, and STX6 were identified, with APOE e4 noted as less prevalent. 3 Despite cognitive dysfunction being a common feature of PSP, 1, 5, 6 the genetic influences on cognition in PSP are not well understood. Moreover, although cognition in general has been shown to be affected by MAPT status 12, 13 and APOE genotype 33 and APOE e4 has been noted as a risk factor for Alzheimer's disease pathology in PSP, 34 the impact of these genes on cognition in PSP has not been investigated using either large samples or comprehensive neuropsychological batteries. In the current sample, cognition varied significantly according to MAPT status, with H1c-specific rs242557/A allele carriers exhibiting better cognitive ability than noncarriers in a number of areas. No other significant genotype effects emerged in this sample of PSP patients, and in contrast to AD, cognition did not vary according to APOE genotype. UPDRS, Unified Parkinson's Disease Rating Scale; PSPRS, Progressive Supranuclear Palsy Rating Scale.
G E R S T E N E C K E R E T A L
These results are the first to demonstrate a connection between genotype and cognition in PSP. Consistent with a priori expectations, cognition varied according to MAPT in this sample of patients with PSP. Given that the H1 haplotype has been shown to be associated with mild cognitive impairment (MCI) 12 and progression from MCI to dementia, 13 we expected H1/H1 PSP patients to perform more poorly on our cognitive battery. However, significant differences in cognitive performance between PSP patients with H1/ H1 and those with H1/H2 were not observed. Because all but 2 study participants were H1 carriers at MAPT rs8070723, we were not able to investigate cognitive differences in PSP patients with H2/H2. However, we detected differences at the MAPT subhaplotype level, with participants with the H1c-specific rs242557/A allele performing better on our neuropsychological test battery. Specifically, cognitive performance on measures of general cognitive function, attention, and executive function were significantly better for MAPT H1c-specific rs242557/A allele carriers than for noncarriers, with performance in a number of other cognitive areas approaching significance.
MAPT rs242557 partially tags H1c, with the A allele being H1c specific and the G allele being H1c nonspecific. 35 The MAPT H1c-specific rs242557/A allele is associated with increased brain MAPT levels 36 and also increased overall risk of PSP. 3 Thus, the observation that rs242557/A allele carriers may have better cognition in PSP is surprising. One possibility is that the observed protection could be an artifact of "survivorship bias," if the MAPT H1c-specific rs242557/A allele in fact worsened cognition, causing many of these participants to be excluded from the sample because of the requirement for MMSE 24. However, this seems somewhat unlikely because the sample is still heavily weighted toward H1c-specific rs242557/A allele participants (233 of 303). Alternatively, the H1c-specific rs242557/A allele may drive increased overall risk of PSP but shape the PSP subtype toward a disease phenotype with relatively less cognitive impairment. Another possibility is that persons without the allele may be more likely to have mixed underlying pathologies (eg, vascular, Alzheimer's disease), which could worsen cognition. Finally, other nearby genes not investigated in this study could be acting as confounding variables.
Cognition was not significantly affected by APOE genotype. However, this finding was not unexpected, given recent hypotheses regarding the manner in which amyloid beta (Ab) influences cognition. The amount of Ab in the brain has been shown to affect cognition, 33 and a connection between APOE status and Ab brain accumulation has been empirically established. [37] [38] [39] [40] [41] Although a direct association between APOE e4 and cognition has been shown in previous studies, [42] [43] [44] recent evidence suggests that tau may act as a mediator between Ab brain accumulation and cognitive impairment in AD. 45 Thus, we conducted follow-up analyses to determine if the combined effect of APOE and MAPT rs242557 was greater on cognition than was MAPT rs242557 alone. Results showed that a combined effect of rs242557/A and APOE e4/4 was not present in our sample. However, it should be noted that the exclusion of PSP patients with MMSE score < 24 may have excluded subjects with both PSP and Alzheimer's disease pathology. 34 Regardless, this finding may indicate that variations associated with the gene responsible for encoding tau has a primary rather than a mediatory effect on cognition in the primary tauopathy of PSP. 
The neurocognitive performance of the sample used in the current study was very similar to a smaller, albeit related sample of patients with PSP. 5 In regard to general cognitive function, the overall DRS-2 averages between our current study and the previous study were within 2 points (ie, approximate 1 percentile difference). Performances of the 2 samples on tests of executive function, language, and attention/concentration showed a similar pattern. For memory tests, performances of the 2 samples were virtually identical. Moreover, the concordance between the pattern of test results highlighted in the current study and our previous study further supports the notion that executive dysfunction is the cardinal feature of cognitive impairment in PSP. 5 Thus, the findings of the current study confirm our earlier results and further indicate that cognitive dysfunction is more prevalent in PSP than commonly thought, even in a sample selected for relatively preserved cognition by excluding those with MMSE < 24.
Although the current study provides insights into the genetic effects on cognition in PSP, some limitations should be noted. First, similar to other multisite studies of rare disorders, the current sample may not fully correspond to the general PSP population. For example, current participants agreed to several hours of testing, exhibited a MMSE score 24 (to exclude frank dementia), and were able to provide informed consent. Thus, the participants making up the current sample may represent a select inclusion group of patients with PSP, and these results might not generalize to all patients with PSP. Second, all patients making up the current sample met NINDS-SPSP criteria for probable or possible PSP. These criteria identify well PSP-RS but are limited in the identification of other PSP phenotypes. Thus, to provide a more complete description of behavioral abnormalities in PSP, future studies should classify patients according to their subtype as the methodology for distinguishing between subtypes improves. Regardless, the current study is the first to empirically establish a relationship between MAPT subhaplotype and cognition in PSP. Further studies are needed to further understand our findings. Note: Means (standard deviations) are listed for cells pertaining to genes. t, P, t statistic and P value.
a P value at the 0.05 level, which approached but did not reach the predetermined alpha 0.01. DRS-2, Dementia Rating Scale -Second Edition; I/P, initiation/perseveration; FAB, Frontal Assessment Battery; CVLT-II SF, California Verbal Learning Test -Second Edition, Short Form; LDFR, long-delay free recall; BNT, Boston Naming Test.
